Our Services and Partners
TEMPUS
Focus: AI-Driven Comprehensive Molecular Profiling
Tempus pairs one of the largest libraries of clinical and molecular data in oncology with an AI-powered platform built to turn that data into decisions at the point of care — not months later, when the window to act has narrowed.
• xT — FDA-approved tumor tissue profiling covering one of the largest reported gene panels available, mapped directly to NCCN Guidelines® and MSK's OncoKB™ so findings translate straight into treatment options.
• xF / xF+ liquid biopsy — a 105-gene blood-based panel that catches actionable mutations tissue biopsy alone can miss; in published NSCLC data.
• xR RNA sequencing — layered alongside DNA profiling to surface fusions and expression changes DNA-only testing overlooks.
One blood draw or biopsy. A full genomic picture. Answers physicians can act on immediately.
NEOSCREEN
Neoscreen Ltd. is an ISO 15189 and 17025 accredited laboratory, for performing molecular diagnostic tests, that has specialized in Clinical Genetic tests since 2007.
Its expertise includes Carrier Screening, Cancer Predisposition, Expanded Newborn Screening, Whole Exome and Whole Genome Sequencing.
Neoscreen long standing expertise in genetic testing has been added up to its flexibility to adapt to frequent changes and needs from the medical community to updated panels and tests to improve diagnosis.
GENPATH
GenPath Diagnostics, a division of Bioreference, offers comprehensive tests and services to help diagnosis and management. GenPath provides urologists with access to a suite of diagnostic testing for a variety of urologic conditions, including prostate cancer, bladder cancer, hereditary cancers, kidney stones, and sexually transmitted infections.
GenPath offers the 4Kscore® Test, a blood test combining four prostate-specific biomarkers with important clinical factors. This tests provides a man's risk for aggressive prostate cancer if a biopsy were to be performed, and offers results that should be considered in the shared decision-making process.
PATHGROUP
PathGroup is committed to providing diagnostic expertise, precision technologies and innovative services and relationships — all to offer clinician partners personalized information for targeted therapies that lead to the best possible patient's outcome.
Led by recognized experts in the field of molecular diagnostics and bioinformatics, PathGroup works with leading individual and contract research partners in developing platforms for improved molecular intelligence. PathGroup molecular diagnostics facility includes a dedicated CLIA validation laboratory to accelerate delivery of new tests and modalities to the physicians and the patients they treat. The portfolio includes several Hematology panels in addition to Endeavor an FDA-cleared test for Molecular Profiling for solid tumors. Endeavor includes a large panel of genes tested by Immunohistochemistry (IHC) and NGS, with a comprehensive report that helps guide clinicians toward beneficial therapies for the patient.
NATERA
Focus: cfDNA testing in Oncology and women's health
Natera is a global leader in cell-free DNA (cfDNA) testing, with diagnostic solutions across Oncology and Women's health.
Oncology: Signatera MRD
Signatera™ is a personalized, tumor-informed circulating tumor DNA (ctDNA) assay designed to assess Molecular Residual Disease (MRD) and monitor cancer recurrence.
Depending on the clinical context, Signatera™ may be used across most cancer types to:
• Assess molecular residual disease after treatment.
• Support decisions regarding adjuvant and Neoadjuvant therapy.
• Monitor for molecular evidence of recurrence.
• Evaluate treatment response in selected patients.
Backed by 100+ peer-reviewed studies, Signatera is now recognized by NCCN as a strong prognostic, risk marker for colon and rectal cancer, and specifically cited in its Merkel cell carcinoma guidelines. Covered by US Medicare across colorectal, breast, bladder, ovarian and lung cancer, plus pan-cancer immunotherapy monitoring. Signatera has also been validated lately for monitoring of Lymphoma. Today, Signatera is one of the most validated MRD tests available on the market.
https://www.natera.com/oncology/
Women's Health: Panorama and Horizon
Panorama® is a non-invasive prenatal screening test based on cfDNA in maternal blood that evaluates the risk of selected abnormal chromosomal conditions affecting the fetus.
It can be performed as early as 9 weeks of pregnancy onwards and uses SNP-based technology to distinguish maternal and fetal DNA providing detailed and accurate screening information.
In addition to trisomies 21, 13 and 18, Panorama can be extended to a series of common microdeletions responsible for several abnormal fetal conditions. The test can also be combined to fetus Rhesus determination, a very useful test in Rhesus-negative mothers.
Horizon: a comprehensive, actionable carrier screening. Horizon helps couples determine the risk of passing on serious genetic conditions to their child. It can be performed either during preconception (ideally) or during pregnancy.
CENATA
Cenata is a genetic diagnostic laboratory that offers the Harmony® Prenatal Test in Germany.
The Harmony® Prenatal Test is one of the most intensely clinically investigated non-invasive prenatal screening tests (NIPT) on chromosomal disorders worldwide. Cenata comprises a team of qualified physicians, including specialists in human genetics, laboratory medicine, and obstetrics and gynecology, for report validation and counseling.
BLUEPRINT GENETICS
BluePrint Genetics is a genetic testing company focused on inherited diseases. With a patient-first mindset, BluePrint Genetics delivers high-quality genetic testing to the global clinical community across 14 medical specialties.
BluePrint Genetics offers high quality genetics testing for a global clinical community by combining a state-of-the-art laboratory process, the latest sequencing technology, AI empowered data-crunching tools and techniques, world-class professionals, and a holistic customer experience approach.
BluePrint Genetics provides clinicians and patients with comprehensive and high-quality tools and resources for diagnosis of genetic conditions for all specialties: pediatrics, cardiology, metabolic disorders, hereditary cancer nephrology, ophthalmology and more.
https://www.blueprintgenetics.com/
LIFE LENGTH
Life Length is the world's leading diagnostic biotech company owing an intellectual property and a proprietary platform technology, based on the measurement of telomere variables and the related trials for aging and age-related diseases.
Based in Madrid, Life Length is the most advanced accredited clinical laboratory holding an Operating License from the Spanish Agency for Medicines and Health Products, and being the only US federal laboratory in Spain.
HealthTAV® monitors the aging process. This test evaluates the extent to which aging is affected by lifestyle and therapeutic interventions. It also analyzes effectiveness of personalized wellness programs and compliance to them.
HealthTAV® uses our patented TAT® (Telomere Analysis Technology), the worldwide most accurate tool for the measurement of telomere length and the determination of the multiple associated variables.
ProsTAV a new telomere - based biomarker for the early diagnosis of prostate cancer. ProsTAV helps reduce by 33% the need for unnecessary biopsies.
AGENDIA
Focus: Precision Oncology for Breast Cancer
Agendia is a precision oncology company dedicated entirely to breast cancer. Its genomic tests interrogate the tumor biology directly, rather than relying only on traditional clinical and histopathological factors like age, tumor grade, and hormone receptor status — helping physicians avoid both under- and over-treatment.
MammaPrint® + BluePrint®
• Both results are available in about 6 business days from a single tissue sample.
• MammaPrint is an FDA-cleared and CE-marked risk stratification test, validated by the MINDACT study, a prospective and randomized clinical trial published in NEJM in 2016 and backed by several other peer-reviewed studies on thousands of patientsBluePrint adds molecular subtyping, showing how a tumor is likely to respond to treatment
• Recommended by international guidelines including ESMO, St. Gallen, ASCO, and NCCN for its prognostic and predictive value in all early stage Breast Cancer categories.
• The two tests together help answer two critical questions:
What are the chances my cancer returns ?
What type of cancer am I dealing with ?
